Taysha Gene Therapies, Inc. (TSHA) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 90 transactions totaling $29.6M, demonstrating a bullish sentiment with $14.3M in net insider flow. The most recent transaction on Jan 26, 2026 involved a sale of 23,849 shares valued at $109.9K.
No significant insider buying has been recorded for TSHA in the recent period.
No significant insider selling has been recorded for TSHA in the recent period.
Based on recent SEC filings, insider sentiment for TSHA is bullish with an Insider Alignment Score of 74/100 and a net flow of $14.3M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Taysha Gene Therapies, Inc. (TSHA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading TSHA stock, having executed 90 transactions in the past 90 days. The most active insider is Paul B. Manning (Executive), who has made 15 transactions totaling $20.1M.
Get notified when executives and directors at TSHA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sale | 23,849 | $4.61 | $109.9K | C-Suite |
| Jan 26, 2026 | P. Nolan Sean | Executive | Sale | 41,312 | $4.61 | $190.4K | |
| Jan 26, 2026 | Nagendran Sukumar | Executive | Sale | 26,918 | $4.61 | $124.1K | |
| Jan 23, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sale | 78,968 | $4.75 | $375.1K | C-Suite |
| Jan 23, 2026 | P. Nolan Sean | Executive | Sale | 136,789 | $4.75 | $649.7K | Large |
| Jan 23, 2026 | Nagendran Sukumar | Executive | Sale | 89,132 | $4.75 | $423.4K | |
| Jan 12, 2026 | P. Nolan Sean | Executive | Award | 648,000 | $N/A | $0 | |
| Jan 12, 2026 | P. Nolan Sean | Executive | Award | 1,008,000 | $N/A | $0 | |
| Jan 12, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Award | 231,000 | $N/A | $0 | C-Suite |
| Jan 12, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Award | 359,000 | $N/A | $0 | C-Suite |
| Dec 1, 2025 | Nagendran Sukumar | Executive | Option Exercise | 260,047 | $1.71 | $444.7K | |
| Dec 1, 2025 | Nagendran Sukumar | Executive | Sale | 260,047 | $4.51 | $1.2M | Large |
| Nov 28, 2025 | Nagendran Sukumar | Executive | Option Exercise | 70,172 | $0.70 | $49.1K | |
| Nov 28, 2025 | Nagendran Sukumar | Executive | Option Exercise | 39,953 | $1.71 | $68.3K | |
| Nov 28, 2025 | Nagendran Sukumar | Executive | Sale | 110,125 | $4.75 | $523.1K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 21 | $21.9M | 72.6% |
Sale(S) | 39 | $7.7M | 25.4% |
Exercise(M) | 4 | $590.9K | 2.0% |
Payment(F) | 1 | $1.9K | 0.0% |
Award(A) | 15 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Conversion(C) | 7 | $0 | 0.0% |
Insiders at Taysha Gene Therapies, Inc. are accumulating shares at an accelerated pace. With 10 insiders making 90 transactions totaling $21.9M in purchases versus $7.7M in sales, the net buying activity of $14.3M signals strong executive confidence. Paul B. Manning (Executive) leads the buying activity with $20.1M in transactions across all time.